Fengjie Liu: College of Pharmacy, Jinan University, Guangzhou, Guangdong, 510632, PR China. ORCID
Lihong Li: College of Pharmacy, Jinan University, Guangzhou, Guangdong, 510632, PR China.
Meng Lan: College of Pharmacy, Jinan University, Guangzhou, Guangdong, 510632, PR China.
Tengteng Zou: College of Pharmacy, Jinan University, Guangzhou, Guangdong, 510632, PR China.
Zhaodi Kong: College of Pharmacy, Jinan University, Guangzhou, Guangdong, 510632, PR China.
Tiange Cai: College of Life Sciences, Liaoning University, Shenyang, 110036, PR China.
Xiaoyu Wu: Advanced Pharmaceutics & Drug Delivery Laboratory, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario, Canada.
Yu Cai: College of Pharmacy, Jinan University, Guangzhou, Guangdong, 510632, PR China. ORCID
Chemotherapeutic drugs are associated with toxic effects. Metastasis is the leading cause of death in breast cancer patients. To evaluate the antitumor effect of paclitaxel (PTX) combined with psoralen-loaded polymeric lipid nanoparticles (PSO-PLNs) in triple-negative breast cancer. After treatment of samples, cell viability, apoptosis, migration, invasion, expression of proteins in the IRAK1/NF-κB/FAK signal pathway, biodistribution and pathological characteristics were detected. Compared with the control group, the PTX + PSO-PLNs group showed increased apoptosis and reduced migration, invasion and expression of phosphorylated IRAK1 and NF-κB, with significant inhibition of tumor growth and lung metastases and no obvious toxicity. Combined administration of PTX and PSO-PLNs exerted a synergistic effect and significantly inhibited the growth and metastasis of triple-negative breast cancer.
